Quality control materials for pharmacogenomic testing in the clinic

被引:3
|
作者
Lin, Guigao [1 ,2 ]
Zhang, Kuo [1 ,2 ]
Han, Yanxi [1 ,2 ]
Li, Jinming [1 ,2 ,3 ]
机构
[1] Beijing Hosp, Natl Ctr Gerontol, Natl Ctr Clin Labs, Beijing, Peoples R China
[2] Beijing Engn Res Ctr Lab Med, Beijing, Peoples R China
[3] 1 DaHua Rd, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
next-generation sequencing; pharmaco-geno-mic testing; quality control materials; CELL LUNG-CANCER; DNA REFERENCE MATERIALS; COLORECTAL-CANCER; BREAST-CANCER; COLLABORATIVE-PROJECT; LABORATORY STANDARDS; CRISPR/CAS9; SYSTEM; MOLECULAR ANALYSIS; ROUNDS; GENERATION;
D O I
10.1515/cclm-2016-0755
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Pharmacogenomics has significantly added to our understanding of drug responses in clinical pharmacology, changing the paradigm of treatment decisions. Interrogations of both inherited and somatic variations for therapeutic purposes are increasingly being adopted in clinics, where quality control (QC) materials are required. However, for many pharmacogenomic tests, the acquisition of well-characterized QC materials is often difficult or impossible. In this review, several sources of appropriate QC materials for therapy-associated genetic testing are discussed. Among them, the novel methods for producing renewable controls that resemble patient samples are highlighted. Owing to technological complexity, more efforts are needed to develop proper controls for next-generation sequencing-based assay.
引用
收藏
页码:926 / 933
页数:8
相关论文
共 50 条
  • [1] The challenges of implementing pharmacogenomic testing in the clinic
    Moyer, Ann M.
    Caraballo, Pedro J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (06) : 567 - 577
  • [2] Preemptive Pharmacogenomic Testing in the Psychiatric Clinic
    Patrinosa, G. P.
    Skokou, M.
    Karaivazoglou, K.
    Ferentinos, P.
    Kalogeropoulou, M.
    Kolios, P.
    Gerasimou, H.
    Bali, P.
    Mitropoulos, K.
    Pagiati, S.
    Douzenis, A.
    Gourzis, F.
    Asimakopoulos, K.
    Tsermpini, E. E.
    PUBLIC HEALTH GENOMICS, 2018, 21 : 2 - 2
  • [3] Pharmacogenomic Testing in the Asthma Clinic: Will Inhaled Corticosteroids Lead the Way?
    Blake, Kathryn
    Raissy, Hengameh
    PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY, 2012, 25 (01) : 44 - 47
  • [4] PRACTICAL MATERIALS TESTING FOR QUALITY-CONTROL
    KONIG, P
    SCHMITZ, KH
    THIEMANN, E
    STAHL UND EISEN, 1977, 97 (18): : 886 - 892
  • [5] Current quality assurance concepts and considerations for quality control of in-clinic biochemistry testing
    Lester, Sally
    Harr, K. E.
    Rishniw, Mark
    Pion, Paul
    JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2013, 242 (02): : 182 - 190
  • [6] Pharmacogenomic, a concept for modern clinic
    Soni, S.
    Bhardwaj, S.
    Dholpuria, R.
    Baniwal, P.
    Thacker, S.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 42 - 42
  • [7] Drug Prescribing and Outcomes After Pharmacogenomic Testing in a Developmental and Behavioral Health Pediatric Clinic
    Patel, Jai N.
    Mueller, Maxine K.
    Guffey, William J.
    Stegman, Joseph
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2020, 41 (01): : 65 - 70
  • [8] HOW MUCH EVIDENCE DO WE NEED BEFORE IMPLEMENTING PHARMACOGENOMIC TESTING IN THE CLINIC?
    Guzauskas, G. F.
    Serbin, M.
    Veenstra, D. L.
    VALUE IN HEALTH, 2015, 18 (03) : A3 - A3
  • [9] Microbiological reference materials for quality control in seed health testing
    Van den Bulk, RW
    Taylor, JD
    SEED HEALTH TESTING: PROGRESS TOWARDS THE 21ST CENTURY, 1997, : 233 - 241
  • [10] The Importance of Reliable Quality Control Materials for Noninvasive Prenatal Testing
    Sistermans, Erik A.
    CLINICAL CHEMISTRY, 2019, 65 (06) : 720 - 722